Compare Palo Alto Networks Inc (PANW) vs Summit Therapeutics Inc (SMMT) Price & Performance

Palo Alto Networks IncTrade

Summit Therapeutics IncTrade

Price performance (Past 24H)

Key statistics

Palo Alto Networks Inc vs Summit Therapeutics Inc — how do they compare? Palo Alto Networks Inc trades at $335.38 (market cap $278.85B), while Summit Therapeutics Inc trades at $14.78 (market cap $11.34B). The key difference: Palo Alto Networks Inc is far larger — about 24.6× Summit Therapeutics Inc's market cap, and Palo Alto Networks Inc is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals.

	PANW	SMMT
Market Cap	$278.85B	$11.34B
Sector	Technology	Health
52-Week High	$358.68	$29.32
52-Week Low	$141.67	$13.05
Enterprise Value	$277.81B	$10.76B

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Palo Alto Networks Inc

No Aura AI signal available yet.

Summit Therapeutics Inc

Summit Therapeutics (SMMT) trades at $13.50, down 2.24% on the day, reflecting a bearish technical trend amid negative profitability. The company reported a net loss of $1.08 billion for 2025, with deeply negative ROE and ROA, though a recent asset sale and positive clinical trial data for its oncology candidate provide some operational catalysts. Cash flow remains volatile, with net cash flow turning negative in 2026 projections.

The investment case is binary, hinging on the success of ivonescimab. While analyst consensus is bullish with a $15.57 price target, high volatility and ongoing fiduciary investigations pose significant risks. The stock offers high-reward potential for risk-tolerant investors betting on clinical success, but fundamental weaknesses and cash burn necessitate caution.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

PANW

Palo Alto Networks to acquire Embrace, adding Real User Monitoring and Synthetics to boost app performance insights.PRNewsWire · 1 day agoBullish Argus Research raises Palo Alto Networks price target to $425 on booming AI-driven cybersecurity demand.Danny Green · 1 day agoBullish Cybersecurity ETFs soar as investors shift from semiconductors amid rising cyber threats and AI risks.ETF Trends · 1 day agoBullish View details →

SMMT

Summit Therapeutics upgraded to Buy after FDA accepts BLA for lung cancer drug ivonescimab.Seeking Alpha · 8 hours agoBullish US extends zero tariffs on imported generic drugs for 2 years, boosting pharma stocks.Finbold · 17 hours agoBullish View details →

About Palo Alto Networks Inc

Palo Alto Networks is a pure-play cybersecurity vendor that sells security appliances, subscriptions, and support into enterprises, government entities, and service providers. The company's product portfolio includes firewall appliances, virtual firewalls, endpoint protection, cloud security, and cybersecurity analytics. The Santa Clara, California, firm was established in 2005 and sells its products worldwide.

About Summit Therapeutics Inc

Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.